Product Images Terazosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Terazosin Hydrochloride NDC 53808-0306 by State Of Florida Doh Central Pharmacy, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Terazosin Hcl 2 mg Caps - Terazoin 2mg(Apotex)

Terazosin Hcl 2 mg Caps - Terazoin 2mg(Apotex)

Terazosin Hcl 5 mg Caps - Terazosin 5mg(Apotex)

Terazosin Hcl 5 mg Caps - Terazosin 5mg(Apotex)

Terazosin HCL is a prescription medication available in the form of SMG CAP. It comes in a package of 30 capsules. The medication is manufactured by Apotex, and the lot number for this particular package is JF3880. The DO LOT number is 111320004. The packaging was done by DOH Central Pharmacy located in Tallahassee, FL 32204. The LT code is included in the packaging along with the lot number for tracking purposes.*

Terazosin Hcl 1 mg Caps - Terazosin1mg (apotex)

Terazosin Hcl 1 mg Caps - Terazosin1mg (apotex)

Terazosin is a prescription drug sold in 30 tablets per bottle, with a concentration of milligrams that is not specified. The bottle has a lot number 020200K and an expiration date of 022810. The package was assembled by DOH Central Pharmacy and contains prescription medication for use only under the orders of a qualified healthcare provider.*

Chemical Structure - terazosin hydrochloride capsules 1

Chemical Structure - terazosin hydrochloride capsules 1

Figure 1 - terazosin hydrochloride capsules 2

Figure 1 - terazosin hydrochloride capsules 2

The text describes a figure and table of Study 1. The figure shows the mean change in total symptom score and mean increase in peak flow rate for Terazosin over a period of months. The table shows the baseline values for both parameters. It also mentions that Terazosin was more effective than the placebo group, with a p-value of less than 0.05.*

Figure 2 - terazosin hydrochloride capsules 3

Figure 2 - terazosin hydrochloride capsules 3

This is a figure presenting the mean change in total symptoms score from baseline in a long-term, open-label, non-placebo controlled study that involved 494 participants. The graph shows the mean change from baseline over a period of 30 months, with measurements taken at each month interval. The mean baseline was 10.7, and there was a statistically significant improvement in symptoms, with p <0.05.*

Figure 3 - terazosin hydrochloride capsules 4

Figure 3 - terazosin hydrochloride capsules 4

This is a graph showing the mean change in peak flow rate from the baseline in a long-term, open-label, non-placebo controlled study. The X-axis shows the months (from 0 to 30) and the Y-axis shows the mean change from baseline. The mean baseline value is 99. There is a statistical significance (p<0.05) at some months compared to the baseline.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.